The association between pre-transfusion hemoglobin levels and thalassemia complications

References

• Cappellini M-D, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT): Thalassaemia International Federation Nicosia, Cyprus; 2014.
   Google Scholar
• Taher A, Vichinsky E, Musallam K, et al. Guidelines for the management of non transfusion dependent thalassaemia (NTDT): Thalassaemia International Federation, Nicosia, Cyprus; 2013.
   Google Scholar
• Thavorncharoensap M, Torcharus K, Nuchprayoon I, et al. Factors affecting health-related quality of life in Thai children with thalassemia. BMC Hematol. 2010;10(1):1.
   Google Scholar
• Cazzola M, Borgna-Pignatti C, Locatelli F, et al. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion. 1997;37(2):135–140.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Stefano PD, Ponchio L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in β-thalassaemia major. Br J Haematol. 1995;89(3):473–478.
   PubMed Web of Science ®Google Scholar
• Malik S, Syed S, Ahmed N. Complications in transfusion–dependent patients of ß-thalassemia major: a review. Pak J Med Sci. 2009;25(4):678–682.
   Web of Science ®Google Scholar
• Saxena A. Growth retardation in thalassemia major patients. Int J Hum Genet. 2003;3(4):237–246.
   Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892.
   PubMed Web of Science ®Google Scholar
• Tantiworawit A, Charoenkwan P, Hantrakool S, et al. Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors. Int J Hematol. 2016;103(6):643–648.
   PubMed Web of Science ®Google Scholar
• Ragab LA, Hamdy MM, Shaheen IA, et al. Blood transfusion among thalassemia patients: a single Egyptian center experience. Asian J Transfus Sci. 2013;7(1):33.
   PubMedGoogle Scholar
• Winichakoon P, Tantiworawit A, Rattanathammethee T, et al. Prevalence and risk factors for complications in patients with Nontransfusion dependent alpha- and beta-thalassemia. Anemia. 2015;2015:793025.
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Porter JB, Piga A, et al. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol. 2015;95(3):244–253.
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970–977.
   PubMed Web of Science ®Google Scholar
• Inati A, Zeineh N, Isma'Eel H, et al. Β-Thalassemia: the Lebanese experience. Clin Lab Haematol. 2006;28(4):217–227.
   PubMedGoogle Scholar
• Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37(1):12–20.
   PubMed Web of Science ®Google Scholar
• Hashemieh M, Azarkeivan A, Radfar M, et al. Prevalence of osteoporosis among thalassemia patients from Zafar adult thalassemia clinic, Iran. Iran J Blood Cancer. 2014;6(3):143–148.
   Google Scholar
• Angchaisuksiri P, Atichartakarn V, Aryurachai K, et al. Risk factors of venous thromboembolism in Thai patients. Int J Hematol. 2007;86(5):397–402.
   PubMed Web of Science ®Google Scholar
• Tantiworawit A, Tapanya S, Phrommintikul A, et al. Prevalence and risk factors for cardiac iron overload and cardiovascular complications among patients with thalassemia in Northern Thailand. Southeast Asian J Trop Med. 2016;47(6):1335–1342.
   PubMed Web of Science ®Google Scholar
• Belhoul KM, Bakir ML, Kadhim AM, et al. Prevalence of iron overload complications among patients with β-thalassemia major treated at Dubai thalassemia Centre. Ann Saudi Med. 2013;33(1):18–21.
   PubMed Web of Science ®Google Scholar
• Teawtrakul N, Jetsrisuparb A, Pongudom S, et al. Epidemiologic study of major complications in adolescent and adult patients with thalassemia in Northeastern Thailand: the E-SAAN study phase I. Hematology. 2018;23(1):55–60.
   PubMed Web of Science ®Google Scholar
• Li CK, Luk CW, Ling SC, et al. Morbidity and mortality patterns of thalassaemia major patients in Hong Kong: retrospective study. Hong Kong Med J. 2002;8(4):255–260.
   PubMedGoogle Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of β-thalassemia major in North America. Blood. 2004;104(1):34–39.
   PubMed Web of Science ®Google Scholar
• Mancuso A, Sciarrino E, Concetta Renda M, et al. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin. 2006;30(1):119–124.
   PubMed Web of Science ®Google Scholar
• Poggiali E, Cassinerio E, Zanaboni L, et al. An update on iron chelation therapy. Blood Transfusion. 2012;10(4):411.
   PubMed Web of Science ®Google Scholar
• Albu A, Barbu CG, Antonie L, et al. Risk factors associated with hypogonadism in β–thalassemia major patients: predictors for a frequent complication of a rare disease. Postgrad Med. 2014;126(5):121–127.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574–578.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193.
   PubMed Web of Science ®Google Scholar
• Inthawong K, Charoenkwan P, Silvilairat S, et al. Pulmonary hypertension in non-transfusion-dependent thalassemia: correlation with clinical parameters, liver iron concentration, and non-transferrin-bound iron. Hematology. 2015;20(10):610–617.
   PubMed Web of Science ®Google Scholar